Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2551

Sort by

Sort Order Select

Journal Articles

Molecular classification improves risk assessment in adult BCR-ABL1– negative B-ALL

Blood (2021) 138 (11): 948–958.

https://doi.org/10.1182/blood.2020010144

Published: 2021

Includes: Supplemental data

Journal Articles

Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy

Kitsada Wudhikarn, Jessica R. Flynn, Isabelle Rivière, Mithat Gönen, Xiuyan Wang, Brigitte Senechal, Kevin J. Curran, Mikhail Roshal, Peter G. Maslak, Mark B. Geyer, Elizabeth F. Halton, Claudia Diamonte, Marco L. Davila, Michel Sadelain, Renier J. Brentjens, Jae H. Park

Blood (2021) 138 (7): 531–543.

https://doi.org/10.1182/blood.2020009515

Published: 2021

Includes: Supplemental data

Journal Articles

Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation

Blood (2021) 138 (4): 331–343.

https://doi.org/10.1182/blood.2020010438

Published: 2021

Includes: Supplemental data

Journal Articles

EBF1 and PAX5 control pro-B cell expansion via opposing regulation of the Myc gene

Rajesh Somasundaram, Christina T. Jensen, Johanna Tingvall-Gustafsson, Josefine Åhsberg, Kazuki Okuyama, Mahadesh Prasad, James R. Hagman, Xun Wang, Shamit Soneji, Tobias Strid, Jonas Ungerbäck, Mikael Sigvardsson

Blood (2021) 137 (22): 3037–3049.

https://doi.org/10.1182/blood.2020009564

Published: 2021

Includes: Supplemental data

Journal Articles

Posttransplant T lymphoblastic lymphoma mimicking Burkitt lymphoma

Jirong Mass, David C. Park

Blood (2021) 137 (21): 3002.

https://doi.org/10.1182/blood.2021011188

Published: 2021

Journal Articles

Primary therapy and survival in patients with Burkitt lymphoma in The Netherlands: a population-based study, 1989-2018

D. E. Issa, R. L. Seefat, O. Visser, S. Zweegman, P. J. Lugtenburg, A. G. Dinmohamed, M. E. D. Chamuleau

Blood (2021) 137 (20): 2848–2851.

https://doi.org/10.1182/blood.2020009552

Published: 2021

Includes: Supplemental data

Journal Articles

B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide

Blood (2021) 137 (16): 2267–2271.

https://doi.org/10.1182/blood.2020008609

Published: 2021

Includes: Supplemental data

Journal Articles

Rapidly deteriorating B-CLL at presentation: clonally related Burkitt leukemia as an atypical Richter transformation?

Chrysovalantou Chatzidimitriou, Theodoros P. Vassilakopoulos

Blood (2021) 137 (16): 2272.

https://doi.org/10.1182/blood.2021010664

Published: 2021

Journal Articles

The treatment of Burkitt lymphoma in adults

Jennifer Crombie, Ann LaCasce

Blood (2021) 137 (6): 743–750.

https://doi.org/10.1182/blood.2019004099

Published: 2021

Journal Articles

Burkitt leukemia with immature B-cell phenotype mimicking acute lymphoblastic leukemia

Kate Raastad, Qin Huang

Blood (2021) 137 (5): 718.

https://doi.org/10.1182/blood.2020009446

Published: 2021

Journal Articles

IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia

Blood (2020) 136 (13): 1520–1534.

https://doi.org/10.1182/blood.2019002655

Published: 2020

Includes: Supplemental data

Journal Articles

Curran KJ, Margossian SP, Kernan NA, et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood. 2019;134(26):2361-2368.

Blood (2020) 136 (11): 1374.

https://doi.org/10.1182/blood.2020008394

Published: 2020

Journal Articles

Preclinical efficacy of humanized, non–FcγR-binding anti-CD3 antibodies in T-cell acute lymphoblastic leukemia

Christine Tran Quang, Benedetta Zaniboni, Romain Humeau, Etienne Lengliné, Marie Emilie Dourthe, Rajkumar Ganesan, Sanjaya Singh, Justin M. Scheer, Vahid Asnafi, Jacques Ghysdael

Blood (2020) 136 (11): 1298–1302.

https://doi.org/10.1182/blood.2019003801

Published: 2020

Includes: Supplemental data

Journal Articles

Triple-hit lymphoma with hyperbasophilic Burkitt-like morphology and solely bone marrow/leukemic phase presentation

Francisco J. Ortuño, Maria-Luz Amigo

Blood (2020) 136 (10): 1212.

https://doi.org/10.1182/blood.2020007134

Published: 2020

Journal Articles

Impaired condensin complex and Aurora B kinase underlie mitotic and chromosomal defects in hyperdiploid B-cell ALL

Blood (2020) 136 (3): 313–327.

https://doi.org/10.1182/blood.2019002538

Published: 2020

Includes: Supplemental data

Journal Articles

Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia

Blood (2020) 136 (2): 210–223.

https://doi.org/10.1182/blood.2019001417

Published: 2020

Includes: Supplemental data

Journal Articles

Early response observed in pediatric patients with relapsed/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells

Wenqun Zhang, Jing Yang, Chunju Zhou, Bo Hu, Ling Jin, Biping Deng, Yang Liu, Shan Wang, Alex H. Chang, Juan Du, Zifen Gao, Yonghong Zhang

Blood (2020) 135 (26): 2425–2427.

https://doi.org/10.1182/blood.2019002008

Published: 2020

Includes: Supplemental data

Journal Articles

Sensitizing Burkitt lymphoma to EBV-CTLs

Helen E. Heslop

Blood (2020) 135 (21): 1822–1823.

https://doi.org/10.1182/blood.2020005492

Published: 2020

Journal Articles

Reduced–dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study

Francisco Pedrosa, Elaine Coustan-Smith, Yinmei Zhou, Cheng Cheng, Arli Pedrosa, Mecneide Mendes Lins, Marcia Pedrosa, Norma Lucena-Silva, Alessandra Maria de Luna Ramos, Ester Vinhas, Gaston K. Rivera, Dario Campana, Raul C. Ribeiro

Blood (2020) 135 (17): 1458–1466.

https://doi.org/10.1182/blood.2019004215

Published: 2020

Includes: Supplemental data

Journal Articles

Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy

Wilhelm Woessmann, Martin Zimmermann, Andrea Meinhardt, Stephanie Müller, Holger Hauch, Fabian Knörr, Ilske Oschlies, Wolfram Klapper, Felix Niggli, Edita Kabickova, Andishe Attarbaschi, Alfred Reiter, Birgit Burkhardt

Blood (2020) 135 (14): 1124–1132.

https://doi.org/10.1182/blood.2019003591

Published: 2020

Includes: Supplemental data

NARROW

Molecular classification improves risk assessment in adult BCR-ABL1– negative B-ALL

Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy

Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation

EBF1 and PAX5 control pro-B cell expansion via opposing regulation of the Myc gene

Posttransplant T lymphoblastic lymphoma mimicking Burkitt lymphoma

Primary therapy and survival in patients with Burkitt lymphoma in The Netherlands: a population-based study, 1989-2018

B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide

Rapidly deteriorating B-CLL at presentation: clonally related Burkitt leukemia as an atypical Richter transformation?

The treatment of Burkitt lymphoma in adults

Burkitt leukemia with immature B-cell phenotype mimicking acute lymphoblastic leukemia

IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia

Curran KJ, Margossian SP, Kernan NA, et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood. 2019;134(26):2361-2368.

Preclinical efficacy of humanized, non–FcγR-binding anti-CD3 antibodies in T-cell acute lymphoblastic leukemia

Triple-hit lymphoma with hyperbasophilic Burkitt-like morphology and solely bone marrow/leukemic phase presentation

Impaired condensin complex and Aurora B kinase underlie mitotic and chromosomal defects in hyperdiploid B-cell ALL

Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia

Early response observed in pediatric patients with relapsed/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells

Sensitizing Burkitt lymphoma to EBV-CTLs

Reduced–dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study

Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only